Clinical Report: Utilizing Artificial Intelligence in Cardio-Oncology

Overview

This review highlights the transformative role of artificial intelligence (AI) in cardio-oncology, particularly in predicting and mitigating cancer therapy-related cardiovascular toxicity (CTR-CVT). By integrating multi-omics data and dynamic imaging, AI enables personalized risk assessment and proactive cardioprotection strategies.

Background

The increasing burden of treatment-related cardiotoxicity from cancer therapies necessitates innovative approaches for risk stratification and management. Traditional methods often fall short in sensitivity and integration of dynamic biomarkers, leading to a critical need for more effective predictive strategies. AI offers a promising solution by harmonizing diverse data streams to enhance patient-specific toxicity trajectories.

Data Highlights

No specific numerical data or trial results were provided in the article.

Key Findings

• AI can integrate multi-omics, imaging, and real-world biosensor data to predict CTR-CVT.
• Dynamic prediction models enable continuous risk reclassification throughout cancer treatment.
• AI-driven mechanistic insights can uncover novel pathways linking oncotherapies to cardiovascular injury.
• Federated learning and explainable AI are emerging solutions to address data heterogeneity and model interpretability challenges.
• AI interventions facilitate a shift from reactive monitoring to preemptive cardioprotection.

Clinical Implications

Healthcare professionals should consider incorporating AI-driven tools in cardio-oncology to enhance early detection and management of cardiotoxicity. Personalized risk mitigation strategies can improve patient outcomes while maintaining the efficacy of cancer treatments.

Conclusion

AI is poised to revolutionize cardio-oncology by providing advanced predictive models and personalized treatment strategies, ultimately safeguarding cardiovascular health in cancer patients. Continued exploration and integration of AI in clinical practice are essential for optimizing patient care.

References

1. The ASCO Post, 2026 -- AI Tool May Predict Cardiac Events in Patients With Cancer and Acute Coronary Syndrome
2. The ASCO Post, 2024 -- Can Artificial Intelligence Predict Treatment Response and Outcomes in Breast Cancer?
3. The ASCO Post, 2024 -- AI in Cancer Care: Embrace the Change
4. Cardio-Oncology Resources & Guidelines | ESC
5. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial - PubMed
6. Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association - PMC
7. The ASCO Post — Can AI Tool Improve Detection of Immune-Related Adverse Events in Patients With Cancer?
8. Cardio-Oncology Resources & Guidelines | ESC
9. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial - PubMed
10. Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association - PMC